Collaboration and LICENSE AgreementCollaboration and License Agreement • May 5th, 2020 • XOMA Corp • Pharmaceutical preparations
This Collaboration and License Agreement (the “Agreement”) is entered into as of February 27, 2020 (the “Effective Date”) is entered into by and between XOMA (US) LLC, a company incorporated under the laws of Delaware, USA having its principal place of business at 2200 Powell Street, Emeryville, California, USA 94608 (“XOMA”), and Cadila Healthcare Limited, a company incorporated under the laws of India having its registered office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway, Ahmedabad-382481, Gujarat, India (“Zydus”). Each of XOMA and Zydus may be referred to herein as a “Party”, or jointly as the “Parties”.
AMENDMENT NO. 3 TO THE LICENSE AGREEMENTThe License Agreement • May 5th, 2020 • XOMA Corp • Pharmaceutical preparations • California
THIS AMENDMENT NO. 3 (this "Amendment") to that certain License Agreement dated as of December 6, 2017, by and between XOMA (US) LLC, a Delaware limited liability company ("XOMA"), having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 and Rezolute, Inc. (formerly known as AntriaBio, Inc.), a Delaware corporation ("Rezolute"), having an address of 201 Redwood Shores Parkway, Redwood City, CA 94065, as amended by Amendment No. 1 dated March 30, 2018, and further amended by Amendment No. 2 dated January 7, 2019 (collectively, the "License Agreement"), is entered into by and between XOMA and Rezolute effective as of March 31, 2020 (the "Effective Date"). Each of XOMA and Rezolute may be referred to herein as a "Party", or jointly as the "Parties". Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.
